Bank of America’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-804
| Closed | -$361 | – | 8543 |
|
|
2024
Q1 | $361 | Hold |
804
| – | – | ﹤0.01% | 7304 |
|
|
2023
Q4 | $595 | Hold |
804
| – | – | ﹤0.01% | 7262 |
|
|
2023
Q3 | $698 | Hold |
804
| – | – | ﹤0.01% | 7283 |
|
|
2023
Q2 | $1.5K | Sell |
804
-1,894
| -70% | -$6.24K | ﹤0.01% | 7187 |
|
|
2023
Q1 | $9.98K | Buy |
2,698
+1,895
| +236% | +$8.75K | ﹤0.01% | 6917 |
|
|
2022
Q4 | $3.05K | Sell |
803
-2
| -0.2% | -$10 | ﹤0.01% | 7151 |
|
|
2022
Q3 | $6K | Hold |
805
| – | – | ﹤0.01% | 7361 |
|
|
2022
Q2 | $17K | Hold |
805
| – | – | ﹤0.01% | 7231 |
|
|
2022
Q1 | $31K | Sell |
805
-18
| -2% | -$622 | ﹤0.01% | 7366 |
|
|
2021
Q4 | $47K | Sell |
823
-189
| -19% | -$12.7K | ﹤0.01% | 7248 |
|
|
2021
Q3 | $73K | Sell |
1,012
-554
| -35% | -$42.4K | ﹤0.01% | 6877 |
|
|
2021
Q2 | $150K | Buy |
1,566
+56
| +4% | +$6.19K | ﹤0.01% | 6280 |
|
|
2021
Q1 | $223K | Buy |
1,510
+384
| +34% | +$69.6K | ﹤0.01% | 5955 |
|
|
2020
Q4 | $158K | Buy |
1,126
+113
| +11% | +$18.3K | ﹤0.01% | 5745 |
|
|
2020
Q3 | $153K | Sell |
1,013
-383
| -27% | -$62.5K | ﹤0.01% | 5453 |
|
|
2020
Q2 | $245K | Buy |
1,396
+940
| +206% | +$157K | ﹤0.01% | 5101 |
|
|
2020
Q1 | $65K | Buy |
+456
| New | +$60.3K | ﹤0.01% | 5761 |
|
|
2019
Q4 | – | Sell |
-8
| Closed | -$1K | – | 7504 |
|
|
2019
Q3 | $1K | Buy |
8
+7
| +700% | +$691 | ﹤0.01% | 7163 |
|
|
2019
Q2 | $0 | Hold |
1
| – | – | ﹤0.01% | 7477 |
|
|
2019
Q1 | $0 | Hold |
1
| – | – | ﹤0.01% | 7484 |
|
|
2018
Q4 | $0 | Hold |
1
| – | – | ﹤0.01% | 7454 |
|
|
2018
Q3 | $0 | Hold |
1
| – | – | ﹤0.01% | 7525 |
|
|
2018
Q2 | $0 | Hold |
1
| – | – | ﹤0.01% | 7389 |
|
|
2018
Q1 | $0 | Hold |
1
| – | – | ﹤0.01% | 7403 |
|
|
2017
Q4 | $1K | Sell |
1
-3
| -75% | -$1.16K | ﹤0.01% | 6944 |
|
|
2017
Q3 | $1K | Buy |
4
+3
| +300% | +$819 | ﹤0.01% | 6961 |
|
|
2017
Q2 | $0 | Hold |
1
| – | – | ﹤0.01% | 7235 |
|
|
2017
Q1 | $0 | Hold |
1
| – | – | ﹤0.01% | 7300 |
|
|
2016
Q4 | $1K | Hold |
1
| – | – | ﹤0.01% | 6938 |
|
|
2016
Q3 | $1K | Hold |
1
| – | – | ﹤0.01% | 6987 |
|
|
2016
Q2 | $1K | Hold |
1
| – | – | ﹤0.01% | 7019 |
|
|
2016
Q1 | $2K | Sell |
1
-4
| -80% | -$5.7K | ﹤0.01% | 6801 |
|
|
2015
Q4 | $12K | Sell |
5
-36
| -88% | -$55.3K | ﹤0.01% | 6621 |
|
|
2015
Q3 | $45K | Buy |
41
+34
| +486% | +$39.4K | ﹤0.01% | 5988 |
|
|
2015
Q2 | $7K | Sell |
7
-39
| -85% | -$42.1K | ﹤0.01% | 6718 |
|
|
2015
Q1 | $47K | Buy |
46
+45
| +4,500% | +$149K | ﹤0.01% | 5689 |
|
|
2014
Q4 | $4K | Sell |
1
-22
| -96% | -$67.4K | ﹤0.01% | 7349 |
|
|
2014
Q3 | $67K | Buy |
23
+14
| +156% | +$46.3K | ﹤0.01% | 6315 |
|
|
2014
Q2 | $35K | Buy |
9
+6
| +200% | +$22.6K | ﹤0.01% | 6890 |
|
|
2014
Q1 | $14K | Buy |
+3
| New | +$15.8K | ﹤0.01% | 7082 |
|
Other funds holding NBSE
Bank of America's NBSE Position: Q2 2024 in Review
Bank of America sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q2 2024, closing a stake of 804 shares — an estimated $361 sold.
Bank of America first reported a position in NBSE in Q1 2014 and held it in 40 quarters. The position peaked at $245K in Q2 2020. 3 funds tracked by Wall St. Rank hold NBSE as of Q2 2024.
- Bank of America reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- Bank of America sold 804 NeuBase Therapeutics, Inc. Common Stock shares in Q2 2024, an estimated $361.
- Bank of America first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q1 2014 and held it in 40 quarters.
- Bank of America's NeuBase Therapeutics, Inc. Common Stock position peaked at $245K in Q2 2020.
- 3 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q2 2024.
Based on Bank of America's 13F filing for Q2 2024, filed 14 Aug 2024.